Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
Eikon Therapeutics reported a Q2 net loss of $88.4 million, narrowing from $105.2 million in the prior year, with a robust cash position of $531.2 million that is expected to fund operations into the second half of 2027. The company announced a key clinical milestone, confirming that the independent Data Monitoring Committee completed the first interim analysis of the Phase 2/3 TeLuRide-006 trial of EIK1001, recommended continuation, and selected a dosing regimen for expansion. Additionally, Eikon appointed Ma.
Key figures
- Net Loss
- $88.4 million
- Ga Expenses
- $17.9 million
- Rd Expenses
- $75.5 million
- Cash Position
- $531.2 million
- Cash runway
- second half of 2027
- Esmo abstracts
- 7
- Rd expenses yoy change
- 9%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.